Effient REMS: FDA Role In Intro Grows; No Safe Use Restrictions
FDA is going to be checking to make sure how many physicians Lilly/Daiichi reach in five key medical practice areas during the first two years of the launch of Effient (prasugrel)
FDA is going to be checking to make sure how many physicians Lilly/Daiichi reach in five key medical practice areas during the first two years of the launch of Effient (prasugrel)